ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the ...
Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency. The posters will be made available on the Amicus website following their respective ...
- Data to highlight latest long-term preclinical efficacy and durability data supporting PBGENE-DMD for the treatment of Duchenne Muscular Dystrophy - - On track to file an IND and/or CTA by the end ...
ROCKVILLE, Md., Sept. 29, 2025 /PRNewswire/ -- REGENXBIO Inc. (RGNX) today announced Chief Medical Officer, Steve Pakola, M.D., will present at the International Congress of the World Muscle Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback